Company: ELV
Filing Date: 2025-07-17
Form Type: 10-Q
Source: 0001156039-25-000114
Chunk: 25

Company: Elevance Health, Inc.
Filing Date: 2025-07-17
Form: 10-Q
Item: Item 8
Chunk 25
---
 period(1)— (2)(1)Net losses on equity securities(1)(2)(8)— Other investments:Gross gains8 3 13 10 Gross losses(6)(13)(99)(25)Other realized losses recognized in income(83)(1)(394)(26)Net losses on other investments(81)(11)(480)(41)Net losses on investments$(131)$(87)$(593)$(253)A primary objective in the management of our fixed maturity and equity portfolios is to maximize total return relative to underlying liabilities and respective liquidity needs. In achieving this goal, assets may be sold to take advantage of market conditions or other investment opportunities as well as tax considerations. Sales will generally produce realized gains and 

-17-

losses. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectations that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.During the three and six months ended June 30, 2025, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $2,682 and $6,021, respectively. During the three and six months ended June 30, 2024, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $3,014 and $8,414, respectively.Accrued Investment IncomeAt June 30, 2025 and December 31, 2024, accrued investment income totaled $284 and $287, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.Securities Lending ProgramsThe fair value of the cash and securities received as collateral for securities loaned at June 30, 2025 and December 31, 2024 was $2,772 and $2,305, respectively. The collateral received was 102% of the market value of the loaned securities at each of June 30, 2025 and December 31, 2024.We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return